Much is being made out of statements made by FDA Commissioner Scott Gottlieb on the subject of insulin. Social media is full of reports of how Commissioner Gottlieb is calling out the insulin companies as if this public rebuke will somehow lower what the patient pays for insulin. Now we hate to burst anyone’s bubble here but it’s time to outline a few of those pesky facts.
We agree completely with Commissioner Gottlieb there should be an easier path for generics and that there are times when insulin companies use shenanigans to protect their lucrative insulin franchises . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.